Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia

Erika Elise Reid, Ann Cameron Haley, Judy H. Borovicka, Alfred Rademaker, Dennis P. West, Maria Colavincenzo, Heather Wickless

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Background: Hair loss may significantly impact an individual's self-image, and studies indicate that patients with both clinically apparent and clinically imperceptible hair loss may have significantly decreased quality of life (QoL). Moreover, clinical severity of hair loss does not necessarily predict impact on QoL. Objective: The aim of this study was to assess QoL in patients (n = 104) with alopecia areata, telogen effluvium, and androgenic alopecia, and to compare QoL with hair loss severity (HLS) as independently rated by both patient and dermatologist. Methods: Questionnaires and clinical assessment tools were used to assess HLS, and QoL was measured by completion of Skindex-16. Results: Overall, patients rated their hair loss as more severe than the dermatologist, and the patient's HLS rating more strongly correlated with QoL than the dermatologist's rating. Clinical assessment of HLS did not reliably predict the patient's QoL, nor did it predict the patient's perception of HLS. Limitations: A convenience sample was recruited from a referral clinic and Skindex-16 has not been validated for use in women's alopecia disorders. Conclusion: These findings indicate dermatologists should address these psychosocial and QoL issues when treating patients with alopecia.

Original languageEnglish (US)
JournalJournal of the American Academy of Dermatology
Volume66
Issue number3
DOIs
StatePublished - Mar 2012

Fingerprint

Alopecia Areata
Alopecia
Quality of Life

Keywords

  • alopecia
  • alopecia areata
  • androgenic alopecia
  • quality of life
  • Skindex-16
  • telogen effluvium

ASJC Scopus subject areas

  • Dermatology

Cite this

Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. / Reid, Erika Elise; Haley, Ann Cameron; Borovicka, Judy H.; Rademaker, Alfred; West, Dennis P.; Colavincenzo, Maria; Wickless, Heather.

In: Journal of the American Academy of Dermatology, Vol. 66, No. 3, 03.2012.

Research output: Contribution to journalArticle

Reid, Erika Elise ; Haley, Ann Cameron ; Borovicka, Judy H. ; Rademaker, Alfred ; West, Dennis P. ; Colavincenzo, Maria ; Wickless, Heather. / Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia. In: Journal of the American Academy of Dermatology. 2012 ; Vol. 66, No. 3.
@article{081fa7c48a704ddba32c97f8987ac414,
title = "Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia",
abstract = "Background: Hair loss may significantly impact an individual's self-image, and studies indicate that patients with both clinically apparent and clinically imperceptible hair loss may have significantly decreased quality of life (QoL). Moreover, clinical severity of hair loss does not necessarily predict impact on QoL. Objective: The aim of this study was to assess QoL in patients (n = 104) with alopecia areata, telogen effluvium, and androgenic alopecia, and to compare QoL with hair loss severity (HLS) as independently rated by both patient and dermatologist. Methods: Questionnaires and clinical assessment tools were used to assess HLS, and QoL was measured by completion of Skindex-16. Results: Overall, patients rated their hair loss as more severe than the dermatologist, and the patient's HLS rating more strongly correlated with QoL than the dermatologist's rating. Clinical assessment of HLS did not reliably predict the patient's QoL, nor did it predict the patient's perception of HLS. Limitations: A convenience sample was recruited from a referral clinic and Skindex-16 has not been validated for use in women's alopecia disorders. Conclusion: These findings indicate dermatologists should address these psychosocial and QoL issues when treating patients with alopecia.",
keywords = "alopecia, alopecia areata, androgenic alopecia, quality of life, Skindex-16, telogen effluvium",
author = "Reid, {Erika Elise} and Haley, {Ann Cameron} and Borovicka, {Judy H.} and Alfred Rademaker and West, {Dennis P.} and Maria Colavincenzo and Heather Wickless",
year = "2012",
month = "3",
doi = "10.1016/j.jaad.2010.11.042",
language = "English (US)",
volume = "66",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia

AU - Reid, Erika Elise

AU - Haley, Ann Cameron

AU - Borovicka, Judy H.

AU - Rademaker, Alfred

AU - West, Dennis P.

AU - Colavincenzo, Maria

AU - Wickless, Heather

PY - 2012/3

Y1 - 2012/3

N2 - Background: Hair loss may significantly impact an individual's self-image, and studies indicate that patients with both clinically apparent and clinically imperceptible hair loss may have significantly decreased quality of life (QoL). Moreover, clinical severity of hair loss does not necessarily predict impact on QoL. Objective: The aim of this study was to assess QoL in patients (n = 104) with alopecia areata, telogen effluvium, and androgenic alopecia, and to compare QoL with hair loss severity (HLS) as independently rated by both patient and dermatologist. Methods: Questionnaires and clinical assessment tools were used to assess HLS, and QoL was measured by completion of Skindex-16. Results: Overall, patients rated their hair loss as more severe than the dermatologist, and the patient's HLS rating more strongly correlated with QoL than the dermatologist's rating. Clinical assessment of HLS did not reliably predict the patient's QoL, nor did it predict the patient's perception of HLS. Limitations: A convenience sample was recruited from a referral clinic and Skindex-16 has not been validated for use in women's alopecia disorders. Conclusion: These findings indicate dermatologists should address these psychosocial and QoL issues when treating patients with alopecia.

AB - Background: Hair loss may significantly impact an individual's self-image, and studies indicate that patients with both clinically apparent and clinically imperceptible hair loss may have significantly decreased quality of life (QoL). Moreover, clinical severity of hair loss does not necessarily predict impact on QoL. Objective: The aim of this study was to assess QoL in patients (n = 104) with alopecia areata, telogen effluvium, and androgenic alopecia, and to compare QoL with hair loss severity (HLS) as independently rated by both patient and dermatologist. Methods: Questionnaires and clinical assessment tools were used to assess HLS, and QoL was measured by completion of Skindex-16. Results: Overall, patients rated their hair loss as more severe than the dermatologist, and the patient's HLS rating more strongly correlated with QoL than the dermatologist's rating. Clinical assessment of HLS did not reliably predict the patient's QoL, nor did it predict the patient's perception of HLS. Limitations: A convenience sample was recruited from a referral clinic and Skindex-16 has not been validated for use in women's alopecia disorders. Conclusion: These findings indicate dermatologists should address these psychosocial and QoL issues when treating patients with alopecia.

KW - alopecia

KW - alopecia areata

KW - androgenic alopecia

KW - quality of life

KW - Skindex-16

KW - telogen effluvium

UR - http://www.scopus.com/inward/record.url?scp=84857458051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857458051&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2010.11.042

DO - 10.1016/j.jaad.2010.11.042

M3 - Article

C2 - 21601948

AN - SCOPUS:84857458051

VL - 66

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 3

ER -